• Home
  • Enzymes

  • Glutamate oxaloacetate transaminase
    (E. coli) 

Glutamate oxaloacetate transaminase
(E. coli) 

Ask a Scientist

High purity Glutamate oxaloacetate transaminase (Escherichia coli) for use in research, biochemical enzyme assays and in vitro diagnostic analysis.

EC 2.6.1.1
CAS: 9000-97-9

aspartate transaminase; L-aspartate:2-oxoglutarate aminotransferase

Recombinant. Highly purified. From Escherichia coli. Electrophoretically homogeneous.
In 3.2 M ammonium sulphate. 
Supplied at ~ 2,500 U/mL. 

Specific activity:
~ 200 U/mg (25oC, pH 8.5 on α-ketoglutaric acid).

Stability: > 4 years at 4oC.

Image unavailable
Product Code
Content/size
Stock
Price
Qty
E-GOTEC
5,000 Units
$221.00

In association with DHL Express Megazyme offers expedited same day shipping on all orders received before 12 noon, DHL offers express shipping to over 220 countries worldwide serving 35 countries next day and 65 within 2 days. For further details visit our delivery page.

We support the following payment methods:

  • Visa
  • MasterCard
  • American Express
  • Cheque
  • Wire Transfer / EFT /ACH

For further details visit our payment page

Add to Cart
Related Products

Aspartame Assay Kit

L-Malic Acid Assay Kit (Analyser Format)

L-Malic Acid Assay Kit (Manual Format)

L-Malic Acid Assay Kit (MegaQuant™ Format)

DESCRIPTION

Glutamate oxaloacetate transaminase (Escherichia coli)

EC 2.6.1.1
CAS: 9000-97-9

Synonyms:
aspartate transaminase; L-aspartate:2-oxoglutarate aminotransferase

Form:
In 3.2 M ammonium sulphate.

Stability: 
> 4 years at 4oC.

Specific activity:
~ 200 U/mg (25oC, pH 8.5 on α-ketoglutaric acid).

Unit definition:
One Unit of L-glutamic-oxaloacetic transaminase activity is defined as the amount of enzyme required to convert one μmole of α-ketoglutarate to L-glutamate per minute in the presence of NADH at pH 8.5 and 25oC.

Specificity:
Catalyzes the reversible transfer of an α-amino group between aspartate and glutamate.

Applications:
Applications in diagnostics and analytical methods in the food and feeds, fermentation, beverages and wine industries. 

Targeting glutamatergic and cellular prion protein mechanisms of amyloid β-mediated persistent synaptic plasticity disruption: Longitudinal studies.

Zhang, D., Qi, Y., Klyubin, I., Ondrejcak, T., Sarell, C. J., Cuello, A. C., Collinge, J. & Rowan, M. J. (2017). Neuropharmacology, 121, 231-246.
Link to Article
Read Abstract
Alzheimer's disease amyloid-β (Aβ) oligomers are synaptotoxic, inappropriately increasing extracellular glutamate concentration and glutamate receptor activation to thereby rapidly disrupt synaptic plasticity. Thus, acutely promoting brain glutamate homeostasis with a blood-based scavenging system, glutamate-oxaloacetate transaminase (GOT), and blocking metabotropic glutamate 5 (mGlu5) receptor or its co-receptor cellular prion protein (PrP), prevent the acute inhibition of long-term potentiation (LTP) by exogenous Aβ. Here, we evaluated the time course of the effects of such interventions in the persistent disruptive effects of Aβ oligomers, either exogenously injected in wild type rats or endogenously generated in transgenic rats that model Alzheimer's disease amyloidosis. We report that repeated, but not acute, systemic administration of recombinant GOT type 1, with or without the glutamate co-substrate oxaloacetate, reversed the persistent deleterious effect of exogenous Aβ on synaptic plasticity. Moreover, similar repetitive treatment reversibly abrogated the inhibition of LTP monitored longitudinally in freely behaving transgenic rats. Remarkably, brief repeated treatment with an mGlu5 receptor antagonist, basimglurant, or an antibody that prevents Aβ oligomer binding to PrP, ICSM35, also had similar reversible ameliorative effects in the transgenic rat model. Overall, the present findings support the ongoing development of therapeutics for early Alzheimer's disease based on these complementary approaches.
Close

Close